Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: A prospective observational study;Efectividad y seguridad de la buprenorfina transdérmica en el tratamiento del dolor crónico en el anciano: Estudio de postautorización observacional y prospectivo

Medicina Clinica

Volumn 128, Issue 6, 2007, Pages 204-210

  Villoria, Clemente Muriel ^a   Garrote, Juan Manuel Pérez Castejón ^b   Magro, Isabel Sánchez ^c   Álvarez, Marta Neira ^c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Clinica Barceloneta   (Spain)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

Buprenorphine; Cohort studies; Cutaneous transdermal administration; Opioid analgesics; Pain

Indexed keywords

BUPRENORPHINE;

AGED; ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; ERYTHEMA; FEMALE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEOPLASM; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP PATTERN; SOMNOLENCE; VOMITING;

EID: 33847702912     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13098717     Document Type: Article

References (22)

1. Català E, Reig E, Artés M, Aliaga L, López JS, Segu JL. Prevalence of pain in the Spanish population: telephone survey in 5000 homes. Eur J Pain. 2002;6:133-40.
2. Barkin RL, Barkin SJ, Barkin DS. Perception, assessment, treatment, and management of pain in the elderly. Clin Geriatr Med. 2005;21:465-90.
3. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry. 2003;60:39-47.
4. Ohayon MM. Relationship between chronic painful physical condition and insomnia. J Psychiatr Res. 2005;39:151-9.
5. Melzack R. Pain - an overview. Acta Anaestesiol Scand. 1999;43:880-4.
6. Schneider JP. Chronic pain management in older adults: with coxibs under fire, what now? Geriatrics. 2005;60:26-31.
7. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943-53.
8. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005;29:297-326.
9. Rossano C, De Luca LF, Firetto V, Fossi F. Activity and tolerabillty of buprenorphine after parenteral and sublingual administration. Clin Ther. 1982;5:61-8.
10. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs. 2003;63:1999-2010.
11. World Health Organization. Cancer pain relief: with a guide to opioid availability. 2nd ed. Geneva: World Health Organization; 1996.
12. Schulmeister L. Transdermal drug patches. Nursing. 2005;35:48-52.
13. Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clinic. 2003;15:193-202.
14. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25:150-68.
15. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004;26:1808-20.
16. Muriel C, Failde I, Mico JA, Neira M, Sánchez-Magro I. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther. 2005;27:451-62.
17. Benson K, Hartz AJ. A comparison of observational studies and randomised, controlled trials. N Engl J Med. 2000;342:1878-86.
18. Collins SL, Edwards J, Moore RA, Smith LA, McQuay HJ. Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough? Pain. 2001;91:189-94.
19. Badia X, Roset M, Montserrat S, Herdman M, Segura A. Versión española del EuroQol: descripción y aplicaciones. Med Clin (Barc). 1999:112 Supl 1:79-85.
20. Committee for Proprietary Medicinal Products. The ICH 2D: post approval safety data management. Note for guidance on definitions and standards for expedited reporting (CPMP/ICH/3945/03). The European Agency for the Evaluation of Medicinal Products. London, 20 November 2003. Disponible en: http://www.emea.eu.int/
21. Committee for Proprietary Medicinal Products. Note for guidance of clinical investigation of medicinal products for treatment of nociceptive pain (CPMP/EWP/612/00). The European Agency for the Evaluation of Medicinal Products. London, 21 November 2002. Disponible en: http://www.emea.eu.int/
22. Breivik H. Opioids in chronic non-cancer pain, indications and controversies. Eur J Pain. 2005;9:127-30.